|
Jul 9
|
Adial Pharmaceuticals Files PCT Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to at least 2045
|
|
Jul 9
|
Alcohol Use Disorder Market Report 2025-2035 Featuring Clearmind Medicine, Purdue Pharma, Psyence Biomedical, Eli Lilly and Co, Tempero Bio,, Nxera Pharma, Novo Nordisk, Adial, Alkermes, Lundbeck
|
|
Jun 25
|
Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product Supply
|
|
Jun 17
|
Top Midday Decliners
|
|
Jun 17
|
Adial Pharmaceuticals Announces Pricing of $3.6 Million Public Offering
|
|
Jun 16
|
Adial Pharmaceuticals Submits Briefing Package to Guide Upcoming FDA Meeting
|
|
Jun 11
|
Adial Pharmaceuticals Advances Toward Phase 3 Development for AD04
|
|
Jun 11
|
EXCLUSIVE: Adial Pharmaceuticals Lead Candidate For Alcohol Use Disorder Advances Toward Phase 3 Trial
|
|
Feb 25
|
Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04
|
|
Feb 25
|
EXCLUSIVE: After FDA Response, Adial Starts Manufacturing Clinical Supplies For Upcoming Phase 3 Program Of Lead Candidate For Alcohol Use Disorder
|
|
Feb 12
|
Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders
|
|
Feb 12
|
EXCLUSIVE: Adial Pharmaceuticals Secures New US Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders
|
|
Oct 23
|
Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference
|
|
Jul 23
|
Adial Pharmaceuticals Advances to Second Cohort in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
|
|
Jul 23
|
EXCLUSIVE: Adial Pharmaceuticals Moves Forward To Second Cohort In Pharmacokinetics Study of AD04 For Alcohol Use Disorder
|
|
Jun 20
|
Adial Pharmaceuticals Announces Publication in Leading Peer-Reviewed Journal Supporting the Potential Efficacy of AD04 as a Precision Medicine for the Treatment of Alcohol Use Disorder
|
|
Jun 20
|
EXCLUSIVE: Adial Pharmaceuticals Announces Publication In Journal Supporting the Potential Efficacy Of AD04 For Alcohol Use Disorder
|
|
May 29
|
Adial CEO to Present at the Spring MicroCap Rodeo Conference on June 6th
|
|
May 15
|
Adial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
|
|
Apr 22
|
EXCLUSIVE: Alcohol Disorder Focused Adial Pharmaceuticals Secures US Patent
|